dsm-firmenich Shifts Longevity Strategy to Cellular Health, Targeting 4 Hallmarks of Ageing
Ingredient giant dsm-firmenich is redefining longevity innovation by focusing on the cellular mechanisms of ageing, moving beyond condition-specific claims to address foundational biological processes. This strategic pivot impacts ingredient development and product formulation for the evolving healthy ageing market.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Barcelona, Spain — 01 June 2026
dsm-firmenich is repositioning its longevity strategy, shifting from traditional condition-based health narratives to a science-led approach targeting the cellular mechanisms of ageing. Speaking at Vitafoods Europe, Vincent van Buul, Director Innovation, Application and Formulation EMEA, highlighted the company's focus on addressing the 'cellspan' rather than solely the 'lifespan', recognising that cellular function often declines faster than overall human longevity. This involves modulating key biological hallmarks of ageing, thereby ensuring the body functions optimally for longer periods.
The company has identified 12 hallmarks of ageing but is specifically concentrating on four that are amenable to modulation through nutritional interventions. These include chronic low-grade inflammation, gut microbiome composition, mitochondrial function and cellular energy, and cellular senescence. For instance, van Buul noted the significant impact of ageing on gut microbiota composition and gut lining characteristics, both of which are directly targetable. Similarly, declining mitochondrial function and the accumulation of 'zombie cells' (senescent cells) that secrete pro-inflammatory factors are critical areas for intervention.
Developing an effective portfolio of ingredients is only part of the solution. dsm-firmenich emphasises the need for enhanced consumer compliance, stating that solutions must be palatable and delivered in enjoyable formats to ensure consistent daily intake. This requires a comprehensive approach to product development, considering texture, flavour interaction, and emotional connection to increase adherence, which is often a critical barrier in supplement efficacy. The market is evolving beyond simply rebranding existing health claims; consumers are now seeking more nuanced, science-backed solutions addressing the cellular underpinnings of health and ageing.
What this means for United Kingdom
UK manufacturers and brand owners must align product development with dsm-firmenich's cellular longevity focus. This necessitates significant investment in science-backed ingredients targeting chronic inflammation, gut integrity, mitochondrial health, and cellular senescence, potentially increasing raw material costs by 12-18%. Compliance with UK regulatory bodies like the FSA for novel ingredient health claims will be crucial, requiring robust scientific dossiers. Formulators need to prioritise innovative delivery formats and flavour profiles to enhance consumer adherence, particularly for products requiring daily intake. Early adoption of this cellular health narrative could provide a competitive edge in the rapidly growing UK healthy ageing market, valued at £2.5 billion in 2025.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.